Emergent BioSolutions Secures $52.7M Government Contract for Smallpox Vaccine
EBS sits 50% above its 52-week low of $5.615 on light trading volume (0.2× avg).
Summary
Emergent BioSolutions announced a $52.7 million contract modification from the U.S. government to supply its ACAM2000® vaccine, ensuring continued revenue from its biodefense portfolio.
Key Events · M&A and Partnerships · EBS
-
$52.7 Million Contract Awarded
Emergent BioSolutions received a contract modification valued at $52.7 million from the U.S. Department of Health and Human Services (ASPR).
-
ACAM2000® Vaccine Supply
The contract is for the supply of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live), ancillaries, and diluent replacement lots to the U.S. government.
-
Continuation of Existing Agreement
This modification exercises Option Year 7 under Emergent's existing 10-year contract with ASPR, with deliveries expected to begin in June 2026.
Analysis · EBS · Life Sciences
This 8-K confirms a significant contract modification for Emergent BioSolutions, securing $52.7 million from the U.S. government to supply its ACAM2000® smallpox and mpox vaccine. This contract, an exercise of Option Year 7 under an existing agreement, represents a substantial revenue stream for the company, reinforcing its role in biodefense preparedness and providing financial stability.
At the time of this filing, EBS was trading at $8.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $433.7M. The 52-week trading range was $5.62 to $14.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.